| PRECLINICAL | evidence | Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits. | Tirzepatide | — | 2026-04-28 |
| PRECLINICAL | evidence | Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review. | Tirzepatide | — | 2026-04-25 |
| PRECLINICAL | evidence | Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study. | Tirzepatide | — | 2026-04-24 |
| PRECLINICAL | evidence | [Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity]. | Tirzepatide | — | 2026-04-23 |
| PRECLINICAL | evidence | LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. | Tirzepatide | Muscle growth & preservation | 2026-04-22 |
| PRECLINICAL | evidence | Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. | Tirzepatide | — | 2026-04-20 |
| PRECLINICAL | evidence | Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles. | Tirzepatide | — | 2026-04-20 |
| PRECLINICAL | evidence | Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity. | LY3298176 | — | 2026-04-17 |
| PRECLINICAL | evidence | Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome. | Tirzepatide | Weight & fat loss | 2026-04-17 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply. | Tirzepatide | — | 2026-04-16 |
| PRECLINICAL | evidence | Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie. | Tirzepatide | Glycemic control | 2026-04-15 |
| PRECLINICAL | evidence | Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes. | Tirzepatide | Weight & fat loss | 2026-04-13 |
| PRECLINICAL | evidence | Weight "regain" in obesity shifts responsibility from biology to personal inadequacy. | Tirzepatide | — | 2026-04-13 |
| PRECLINICAL | evidence | Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro. | Mounjaro | — | 2026-04-13 |
| PRECLINICAL | evidence | Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation. | Tirzepatide | — | 2026-04-10 |
| PRECLINICAL | evidence | Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials. | Tirzepatide | — | 2026-04-10 |
| PRECLINICAL | evidence | Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants. | Tirzepatide | — | 2026-04-09 |
| PRECLINICAL | evidence | Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity. | Tirzepatide | — | 2026-04-08 |
| PRECLINICAL | evidence | Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes. | Tirzepatide | Glycemic control | 2026-04-07 |
| PRECLINICAL | evidence | Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. | Tirzepatide | — | 2026-04-06 |
| PRECLINICAL | evidence | Drug-induced liver injury secondary to tirzepatide. | Tirzepatide | Glycemic control | 2026-04-03 |
| PRECLINICAL | evidence | The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation. | Mounjaro | Weight & fat loss | 2026-04-02 |
| PRECLINICAL | evidence | Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report. | Tirzepatide | — | 2026-04-02 |
| PRECLINICAL | evidence | Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | A Massive Type IV Hiatal Hernia With Gastric Volvulus and the Complicated Road to Recovery. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials. | Tirzepatide | Weight & fat loss · n = 20015 | 2026-04-01 |
| PRECLINICAL | evidence | Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. | Mounjaro | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study. | Tirzepatide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? | Tirzepatide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Biomimetic Hematoma Enables Healing in Complex Periprosthetic Fracture Nonunion with Multiple Comorbidities: A Case Report. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Commentary on "Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study". | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer. | Tirzepatide | — | 2026-04-01 |
| PRECLINICAL | evidence | Crossing the line: BMI category changes with tirzepatide. | Tirzepatide | — | 2026-04-01 |